Genvec Inc (GNVC) Financial Statements (2024 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,6674,8929,6306,3337,0156,579
Cash and cash equivalents3,6674,8929,6306,3337,0156,579
Receivables2217649140166263
Other undisclosed current assets3,7693,8735198241,9063,665
Total current assets:7,4588,94110,1987,2979,08710,507
Noncurrent Assets
Property, plant and equipment191230231253279248
Restricted cash and investments      97
Other noncurrent assets5897979797 
Total noncurrent assets:249327328350376345
TOTAL ASSETS:7,7079,26810,5267,6479,46310,852
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,8479678891,1351,694938
Employee-related liabilities 684   450 
Accounts payable9579678891,1351,096938
Accrued liabilities 206   148 
Other undisclosed current liabilities 524519399 755
Total current liabilities:1,8471,4911,4081,5341,6941,693
Noncurrent Liabilities
Liabilities, other than long-term debt969782868991
Other liabilities969782868991
Other undisclosed noncurrent liabilities1,0591,6351,949   
Total noncurrent liabilities:1,1551,7322,031868991
Total liabilities:3,0023,2233,4391,6201,7831,784
Equity
Equity, attributable to parent4,7056,0457,0876,0277,6809,068
Common stock22323171717
Additional paid in capital295,333295,125294,959292,710292,508292,287
Accumulated other comprehensive loss(3)(1)  (5)(38)
Accumulated deficit(290,627)(289,102)(287,895)(286,700)(284,840)(283,198)
Total equity:4,7056,0457,0876,0277,6809,068
TOTAL LIABILITIES AND EQUITY:7,7079,26810,5267,6479,46310,852

Income Statement (P&L) ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Revenues
(Revenue, Net)
2217326290160193
Gross profit:2217326290160193
Operating expenses(2,134)(1,703)(1,740)(2,149)(1,805)(1,704)
Operating loss:(2,112)(1,530)(1,714)(1,859)(1,645)(1,511)
Nonoperating income (expense)587323519   
Interest and debt expense   (250)   
Other undisclosed income from continuing operations before equity method investments, income taxes 250     
Loss from continuing operations:(1,275)(1,207)(1,445)(1,859)(1,645)(1,511)
Loss before gain (loss) on sale of properties:(1,275)(1,207)(1,445)(1,859)(1,645)(1,511)
Net loss:(1,275)(1,207)(1,445)(1,859)(1,645)(1,511)
Other undisclosed net income (loss) attributable to parent (250) 250(1)36
Net loss available to common stockholders, diluted:(1,525)(1,207)(1,195)(1,860)(1,642)(1,505)

Comprehensive Income ($ in thousands)

3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
Net loss:(1,275)(1,207)(1,445)(1,859)(1,645)(1,511)
Comprehensive loss:(1,275)(1,207)(1,445)(1,859)(1,645)(1,511)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(252)(1)250436(1)
Comprehensive loss, net of tax, attributable to parent:(1,527)(1,208)(1,195)(1,855)(1,609)(1,512)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: